QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
In the U.S., fewer men have been undergoing PSA screening since 2008, (largely due to the U.S. Preventive Services Task Force (USPSTF) revision of national guidelines. In 2008, the USPSTF recommended against screening men older than 75 years of age….
The International Society of Urologic Pathology (ISUP) 2019 modification of the prostate cancer grading system is now well-established for diagnosing and managing prostate cancer patients. Recently, some authors have called for removing the cancer label from Gleason grade group 1…
Micro-ultrasound (MicroUS) is an advanced imaging technology used to detect prostate cancer in men. It has high resolution and is as effective as MRI in identifying clinically significant prostate cancer. Researchers are studying how to best use MicroUS, and ongoing…
Diet and lifestyle can affect prostate cancer rates; good nutrition can help lower the risk and progression of prostate cancer. One study showed that a healthy diet and exercise reduced a hormone called IGF-I, which is linked to higher cancer…
Exercise can play a significant role in fighting prostate cancer. Factors like being inactive, smoking, excess weight, and consuming spicy, fatty and fried foods create an environment that encourages the growth of prostate cancer. Unfortunately, many men with prostate cancer…
A multiinstitutional study from Canada reported that pairing aerobic resistance exercises with computerized cognitive training could be beneficial for older adults with mild cognitive impairment (MCI). This combination may help improve cognition and potentially delay the onset of dementia. They…
There is an old saying, “If it ain’t broke, don’t fix it.” That definitely applies to many things but not to our bodies. The science on this topic is in: Being physically active is not only important for our health…
Cancer is the second leading cause of death worldwide and cases are estimated to increase and reach 21.4 million by 2030. The main reasons for this increase are a combination of growing and aging populations and medical advances leading to…
In a large multinational, multiinstitutional clinical trial, researchers investigated the combination of enzalutamide and androgen deprivation therapy (ADT) to enhance cancer patients’ survival and delay disease progression. The results showed that enzalutamide plus ADT improved radiographic progression-free survival compared to…
Talazoparib is a drug in the class called “PARP inhibitors” that have been shown to be effective in treating advanced cancers, particularly in carriers of BRCA and other DNA repair genetic variants. Enzalutamide is a second-generation form of hormonal therapy…
"*" indicates required fields
